1. Home
  2. CVR vs PHGE Comparison

CVR vs PHGE Comparison

Compare CVR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Rivet & Machine Co.

CVR

Chicago Rivet & Machine Co.

HOLD

Current Price

$13.57

Market Cap

10.4M

Sector

Industrials

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$6.19

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVR
PHGE
Founded
1920
2015
Country
United States
United States
Employees
N/A
57
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
9.2M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CVR
PHGE
Price
$13.57
$6.19
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
2.7K
64.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,986,627.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.15
$0.25
52 Week High
$15.00
$8.50

Technical Indicators

Market Signals
Indicator
CVR
PHGE
Relative Strength Index (RSI) 46.92 53.69
Support Level $13.32 $0.41
Resistance Level $14.47 $6.28
Average True Range (ATR) 0.51 0.96
MACD -0.02 0.06
Stochastic Oscillator 18.29 55.04

Price Performance

Historical Comparison
CVR
PHGE

About CVR Chicago Rivet & Machine Co.

Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: